Prostatype Genomics study shows low-risk group records zero prostate cancer deaths over 20 years

A 20-year follow-up study of 137 prostate cancer patients presented by Prostatype Genomics showed that patients identified as low-risk by the Prostatype test recorded zero prostate cancer deaths. The study, which followed patients from Uppsala University Hospital, indicated Prostatype outperformed the NCCN risk framework in identifying patients likely to die from prostate cancer. Data has been submitted for peer review.